Marika Crohns
Harvard Medical School, Finalnd
Abstract Title: The Role of AI in Oncology
Biography:
Dr. Marika Crohns is a distinguished healthcare executive with over 20 years of international leadership experience. She holds an MD and PhD, is board-certified in Oncology and Radiation Therapy, and is additionally certified in Pharmaceutical Medicine, complemented by commercial training. An award-winning keynote speaker, Dr. Crohns is a strong advocate for the adoption of novel technologies in healthcare and the advancement of innovation in oncology. She is also the author of a pioneering research book in her field. Currently, she is employed by AstraZeneca. Her career reflects a consistent commitment to transformative oncology, strategic leadership, and improving global health outcomes.
Research Interest:
Artificial Intelligence (AI) is rapidly reshaping oncology, offering unprecedented opportunities to transform how cancer is detected, diagnosed, and treated. Through sophisticated algorithms and machine learning techniques, AI strengthens every stage of the cancer care pathway-from early identification to long-term follow-up. In diagnostics, AI-driven image analysis enables faster and more precise interpretation of radiological and pathological data, boosting detection accuracy for cancers such as breast, lung, and skin. Predictive models that integrate genetic, clinical, and demographic information help identify individuals at elevated risk, supporting more targeted and personalized screening strategies. AI is also redefining treatment planning. Advanced predictive tools assist clinicians in selecting optimal therapies by analyzing extensive datasets that include clinical outcomes, genomic signatures, and real-time patient information. This personalized approach enhances treatment effectiveness while reducing adverse effects. In radiotherapy, AI streamlines planning by automating tumor delineation and optimizing dose distribution. Within research, AI accelerates drug discovery and clinical trial development by pinpointing promising therapeutic targets and forecasting patient responses. Natural language processing (NLP) further supports clinicians by synthesizing large volumes of scientific literature and highlighting emerging evidence. Beyond active treatment, AI strengthens survivorship care through remote monitoring technologies-such as wearables and mobile health platforms-that provide continuous feedback and enable early detection of recurrence. Despite these advances, challenges persist, including ethical concerns, data privacy, and the need for transparent AI decision-making. This abstract examines AI’s transformative impact on oncology, emphasizing its capacity to personalize care, improve efficiency, and enhance patient outcomes. By addressing current limitations and fostering collaboration across disciplines, AI is poised to significantly shape the future of cancer care.